What is unique about STC-nEPS technology that makes you stand apart from other cell therapy options?
Stem cell therapy opened up a whole new paradigm in medical history but with much limitations and controversy.
STC-nEPS technology proposes to you a safe-powerful-available(cost efficient) alternative to various diseases men have been suffering from.
We’re just taking off with this novel discovery but one that promises us so much for the future of our mankind, with endless opportunities.
To date, there is no permanent cure for diabetes except for pancreas transplantation or injecting pancreatic beta cell that secrete insulin.
Benefits to include, 1)freedom from daily insulin shots, 2)no fear of blood glucose level rising, 3) efficient means to enjoy a healthier, hassle-free lifestyle.
CNS-related diseases – Parkinson’s Disease
There’s no coming back from a dead neuronal cell thus there was no efficient cure to date for CNS-diseases.
Regenerating a neuronal cell using a pluripotent stem cell to restore its original function is believed to be the only solution to this issue. While regenerating the neurons, our cell therapy possesses added advantages of protecting the neurons.
Others may include cell supply/ drug screening – Unlike conventional iPS cells, our cells are mass producible (cost efficient/ no waiting) owing to our in-house cultivation technology and high success rate in cell production.
Our primary market for expansion will be in the U.S., to expand to EU and Japan.
If you have a query, please do not hesitate to contact to the below email.
Up to now bBHC’s major source of revenue is from the global sales of cosmetics.
Our immediate goal by Q2 would be to secure some 50mil US$, to be used in expanding facility & infrastructure and also to reach up to Phase II. in clinical for type II. Diabetes and CNS related diseases.
Other than licensing in our derived cells, there exists much options among which include collaboration & per milestone investment.
Seoul, South Korea
Provided that all goes well, we hope to be the U.S. by Q4 this year.
Dec. 31, 2016